BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 16336754)

  • 1. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
    Kim GP; Grothey A
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on clinical data with regimens inhibiting angiogenesis and epidermal growth factor receptor for patients with newly diagnosed metastatic colorectal cancer.
    Cohen DJ; Hochster HS
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S21-7. PubMed ID: 18361803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab in previously treated colorectal cancer.
    Starling N; Cunningham D
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S28-33. PubMed ID: 15871763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developments in combination chemotherapy for colorectal cancer.
    Goetz MP; Grothey A
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):627-37. PubMed ID: 15270666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New perspectives in predicting response to chemotherapy in colorectal cancer].
    Sempere L; Jover R
    Gastroenterol Hepatol; 2008 Nov; 31(9):580-6. PubMed ID: 19091247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
    Jackson C; Cunningham D
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Schmoll HJ
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
    Kuebler JP; de Gramont A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxaliplatin in the treatment of colorectal cancer.
    Kim GP; Erlichman C
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):281-94. PubMed ID: 17428157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic treatment of advanced colorectal carcinoma.
    van Laarhoven HW; Punt CJ
    Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):283-9. PubMed ID: 15195891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biotherapy in colorectal cancer].
    Des Guetz G
    J Chir (Paris); 2005; 142(5):291-6. PubMed ID: 16292207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and emerging therapies for metastatic colorectal cancer: applying research findings to clinical practice.
    Hecht JR
    Am J Health Syst Pharm; 2008 Jun; 65(11 Suppl 4):S15-21; quiz S22-4. PubMed ID: 18499885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I; Hitre E
    Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxaliplatin: a new agent for colorectal cancer.
    Pelley RJ
    Curr Oncol Rep; 2001 Mar; 3(2):147-55. PubMed ID: 11177747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapies for advanced colorectal cancer.
    Aggarwal S; Chu E
    Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adjuvant chemotherapy for colorectal carcinoma].
    Schallhorn A
    Internist (Berl); 2000 Apr; 41(4):387-8. PubMed ID: 10798189
    [No Abstract]   [Full Text] [Related]  

  • 20. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.